Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15756024rdf:typepubmed:Citationlld:pubmed
pubmed-article:15756024lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:15756024lifeskim:mentionsumls-concept:C0001554lld:lifeskim
pubmed-article:15756024lifeskim:mentionsumls-concept:C0144576lld:lifeskim
pubmed-article:15756024lifeskim:mentionsumls-concept:C1122962lld:lifeskim
pubmed-article:15756024lifeskim:mentionsumls-concept:C1443775lld:lifeskim
pubmed-article:15756024lifeskim:mentionsumls-concept:C0549178lld:lifeskim
pubmed-article:15756024lifeskim:mentionsumls-concept:C1704419lld:lifeskim
pubmed-article:15756024pubmed:issue5lld:pubmed
pubmed-article:15756024pubmed:dateCreated2005-3-9lld:pubmed
pubmed-article:15756024pubmed:abstractTextGefitinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. Continuous inhibition of EGFR signaling is thought necessary for optimal inhibition of tumor cell proliferation. We hypothesized that continuous gefitinib may antagonize the effects of cytotoxics that inhibit tumor cells in other phases of the cell cycle. Furthermore, we hypothesized that intermittent dosing would allow for dose escalation and greater inhibition of EGFR-dependent antiapoptotic pathways.lld:pubmed
pubmed-article:15756024pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15756024pubmed:languageenglld:pubmed
pubmed-article:15756024pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15756024pubmed:citationSubsetIMlld:pubmed
pubmed-article:15756024pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15756024pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15756024pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15756024pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15756024pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15756024pubmed:statusMEDLINElld:pubmed
pubmed-article:15756024pubmed:monthMarlld:pubmed
pubmed-article:15756024pubmed:issn1078-0432lld:pubmed
pubmed-article:15756024pubmed:authorpubmed-author:ScherHoward...lld:pubmed
pubmed-article:15756024pubmed:authorpubmed-author:SolitDavid...lld:pubmed
pubmed-article:15756024pubmed:authorpubmed-author:RosenNealNlld:pubmed
pubmed-article:15756024pubmed:authorpubmed-author:KrisMark GMGlld:pubmed
pubmed-article:15756024pubmed:authorpubmed-author:SheYuhongYlld:pubmed
pubmed-article:15756024pubmed:authorpubmed-author:LoboJoseJlld:pubmed
pubmed-article:15756024pubmed:authorpubmed-author:SirotnakFrank...lld:pubmed
pubmed-article:15756024pubmed:issnTypePrintlld:pubmed
pubmed-article:15756024pubmed:day1lld:pubmed
pubmed-article:15756024pubmed:volume11lld:pubmed
pubmed-article:15756024pubmed:ownerNLMlld:pubmed
pubmed-article:15756024pubmed:authorsCompleteYlld:pubmed
pubmed-article:15756024pubmed:pagination1983-9lld:pubmed
pubmed-article:15756024pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:meshHeadingpubmed-meshheading:15756024...lld:pubmed
pubmed-article:15756024pubmed:year2005lld:pubmed
pubmed-article:15756024pubmed:articleTitlePulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.lld:pubmed
pubmed-article:15756024pubmed:affiliationDepartment of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. solitd@mskcc.orglld:pubmed
pubmed-article:15756024pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15756024pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:15756024pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:15756024pubmed:publicationTypeResearch Support, N.I.H., Extramurallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15756024lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15756024lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15756024lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15756024lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15756024lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15756024lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15756024lld:pubmed